Biotech Startups

SynthBiome designs synthetic growth media that replicate the physiological conditions bacterial pathogens encounter in human infection sites, including media mimicking cystic fibrosis sputum and chronic wound environments. Its models serve researchers and clinical teams for drug development and antibiotic treatment selection.

1 investor

Synthesa provides AI-assisted evidence synthesis services—including systematic reviews, abstract screening, data extraction, and frequentist and Bayesian meta-analyses—with expert validation, for CROs, medcomms agencies, pharma, medical device, biotech, and MedTech teams. It is also developing a self-service meta-analysis platform for researchers with their own datasets.

1 investor

Synthesize develops generative AI models that simulate human tissue responses to drugs and diseases for clinical trial design. The company helps biotech and pharmaceutical development teams de-risk trials, identify biomarkers, and extend early-phase data by generating synthetic patient cohorts.

1 investor

Synthetic Design Lab develops engineered therapeutic platforms and AI-driven antibody design technologies for precision medicine and cancer immunotherapy. The company builds protein engineering and antibody drug conjugate solutions for pharmaceutical development.

1 investor

Syrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.

1 investor

Green World Solutions is an Estonian company behind the Black Stuff brand, which produces dietary supplements designed to support microbiome health and immunity. The company collaborates with an Institute of Innovative Biomedical Technologies and conducts third-party laboratory testing of its natural-ingredient products.

1 investor

T.Rx Capital is a venture capital firm that invests in and helps build early-stage biotech, healthcare, and medical technology companies, focusing on drug discovery, advanced therapeutic modalities, medical devices, diagnostics, and healthcare software.

1 investor

Taaleri Bioteollisuus is an investment manager that runs private equity funds and joint ventures targeting growth companies in the bio-economy and circular-economy markets, focusing on Northern European firms. Its Bioteollisuus I fund invests in new-technology, industrial-scale bioeconomy production facilities in Finland and Europe.

1 investor

TAAV is a contract development and manufacturing organization (CDMO) that produces neDNA, an enzymatic DNA technology that serves as an alternative to plasmid DNA for manufacturing recombinant adeno-associated viruses (rAAV) used in gene therapy. The company works with biopharma companies, research centers, and other entities developing rAAV-based gene therapy programs.

1 investor

Tabula Bio uses machine learning to design in-context DNA algorithms that can outpace microbial evolution and treat infectious disease, positioning itself as an alternative to traditional antibiotic and drug development. The company applies AI to design new DNA faster than pathogens can evolve resistance, and states it is already treating patients.

1 investor

Tacit Machines builds data and compute infrastructure that connects laboratory experiments with large-scale computational analysis. Its systems are intended for biology research groups and biotech organizations that need to move wet-lab data into GPU-based processing pipelines.

1 investor

Tactile Therapeutics is a venture-funded biotechnology company working on Targeted Protein Degradation.

1 investor

TAG Therapeutics develops TELOBLOCK, an antisense nucleotide therapy that inhibits the DNA damage response at short or damaged telomeres to reduce cellular senescence, targeting telomere biology disorders and age-related diseases such as idiopathic pulmonary fibrosis and bone marrow failure. The company also explores ex-vivo applications to improve immune cell fitness for bone marrow transplantation and cancer immunotherapies.

1 investor

The company develops DNA aptamers—single-stranded oligonucleic acid therapeutics—using proprietary artificial base-pair technology for drug discovery and medical applications. The platform aims to create effective and safe pharmaceuticals that can be widely distributed, while also enabling applications in medical devices and diagnostics.

1 investor

Tait Labs upcycles industrial by-products into health ingredients. The site is currently a placeholder while the company rebuilds its website.

1 investor

Talawar Therapeutics develops bispecific antibodies that combine two disease-driving pathways in a single therapy for greater and more durable treatment effect. Its lead program, TALA-125, is an anti-IL-13 x anti-IL-18 bispecific aimed at first-line patients and those who have failed prior therapies.

1 investor

TANDEM Therapeutics is an early-stage biopharmaceutical company developing precision therapies for fibrosis and fibrotic cancers using Matrix Targeting Peptides that address disease-associated extracellular matrix alterations. Its pipeline of conditionally targeted therapies is based on research from ETH Zürich and the Paul Scherrer Institute in matrix mechanobiology.

1 investor

Tandem Repeat develops Squitex, a biobased fiber material derived from squid ring teeth protein using genetic sequencing tools, intended as an alternative to petroleum-based fibers for the textile industry. The company applies biomimetic design to create durable, more sustainable textile materials.

1 investor

1 investor

Taninpardaz Pasargad develops cochlear implant systems and hearing-related medical devices and services for deaf and hard-of-hearing patients in Iran.

1 investor

New York-based heart-on-a-chip company with a platform for cardiac tissue models.

1 investor

Pedestal Health builds longitudinal, disease-specific observational data and patient cohorts within real clinical practice through embedded health system partnerships, supporting research from observational studies to prospective and interventional trials. It serves life sciences companies and health systems for clinical development, regulatory strategy, access planning, and care delivery, with current depth in hepatology, dermatology, and gastroenterology.

1 investor

Tarsons manufactures a range of plastic labware products for life sciences research, including bottles, flasks, centrifuge ware, cryo labware, and liquid handling systems. The company serves academic, pharmaceutical, biotechnology, clinical research, and industrial customers across 40+ countries.

1 investor

1 investor